About Cellular tumor antigen p53
Cellular tumor antigen p53 (TP53) is a protein
from Homo sapiens identified by UniProt accession
P04637, 393 residues long.
MolForge cross-references it against 0 known binders and
2,960 disease associations.
Target properties
| Protein name | Cellular tumor antigen p53 |
|---|
| UniProt accession | P04637 |
|---|
| Gene | TP53 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 393 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (2960)
Diseases linked to this target (Open Targets).
- Li-Fraumeni syndrome · score 0.88
- hepatocellular carcinoma · score 0.81
- head and neck squamous cell carcinoma · score 0.79
- lung adenocarcinoma · score 0.76
- acute myeloid leukemia · score 0.75
- breast adenocarcinoma · score 0.74
- prostate adenocarcinoma · score 0.73
- chronic lymphocytic leukemia · score 0.72
- gastric adenocarcinoma · score 0.71
- colorectal cancer · score 0.71
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P04637-F1 | alphafold | PREDICTED | 75.05 | — |
Amino-acid sequence (393 residues)
MEEPQSDPSV EPPLSQETFS DLWKLLPENN VLSPLPSQAM DDLMLSPDDI EQWFTEDPGP DEAPRMPEAA PPVAPAPAAP TPAAPAPAPS WPLSSSVPSQ KTYQGSYGFR LGFLHSGTAK SVTCTYSPAL NKMFCQLAKT CPVQLWVDST PPPGTRVRAM AIYKQSQHMT EVVRRCPHHE RCSDSDGLAP PQHLIRVEGN LRVEYLDDRN TFRHSVVVPY EPPEVGSDCT TIHYNYMCNS SCMGGMNRRP ILTIITLEDS SGNLLGRNSF EVRVCACPGR DRRTEEENLR KKGEPHHELP PGSTKRALPN NTSSSPQPKK KPLDGEYFTL QIRGRERFEM FRELNEALEL KDAQAGKEPG GSRAHSSHLK SKKGQSTSRH KKLMFKTEGP DSD
Explore Cellular tumor antigen p53 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets